Cancer Forums and News by PhD's

News | Forums

Go Back   Cancer Forums and News by PhD's > Cancer Forums and News

Cancer News


Cancer Review


Recent Forum Topics

Leading leukemia experts: High leukemia treatment costs may be harming patients
By Dross at 2013-04-26 00:29

 The increasing cost of treatments for chronic myeloid leukemiaterm (CML) in the United States has reached unsustainably high levels and may be leaving many patients under- or untreated because they cannot afford care, according to a Blood Forum article supported by nearly 120 CML experts from more than 15 countries on five continents and pu

read more | 4158 reads

Clinical trial delivers results in leukemia patients
By Dross at 2012-11-30 21:21

Two researchers from the Huntsman Cancer Institute have published results for a recent clinical trial using the drug ponatinib for the treatment of chronic myelogenous leukemia in patients that were refractory to Gleevec and other standard treatments for Philadelphia chromosome positive hematological neoplasms.

Conducted at five cancer centers, this phase one trial demonstrated that ponatinib was highly active in patients with CML and Ph++ ALL who were resistant to approved tyrosine kinase inhibitors.

read more | 6 comments | 2601 reads

Bone marrow transplant survival more than doubles for young high-risk leukemia patients
By Dross at 2011-07-15 20:56


Bone marrow transplant survival more than doubled in recent years for young, high-risk leukemiaterm patients treated at St. Jude Children's Research Hospital, with patients who lacked genetically matched donors recording the most significant gains. The results are believed to be the best ever reported for leukemia patients who underwent bone marrow transplantation.

read more | 19399 reads

Researchers make critical leukemia stem cell discovery
By Dross at 2010-12-15 05:33

Researchers at King's College London have discovered that leukaemic stem cells can be reversed to a pre-leukaemic stage by suppressing a protein called beta-catenin found in the blood.

They also found that advanced leukaemic stem cells that had become resistant to treatment could be 're-sensitised' to treatment by suppressing the same protein.

read more | 3019 reads

New clue in leukemia mystery: Researchers identify 'poison' employed by deadly enzyme mutations
By Dross at 2010-12-04 00:16

NEW YORK (Dec. 2, 2010) -- There is new hope for people with acute myelogenous leukemiaterm (AML), a fast-growing cancer of the blood and bone marrow. Research led by Weill Cornell Medical College and published today in the online edition of the journal Cancer Cell reveals a surprising and unexpected cancer-causing mechanism. The investigators discovered that newly identified mutant enzymes in AML create a chemical poison to cause leukemia.

read more | 2729 reads

Tiny RNA shown to cause multiple types of leukemia
By Dross at 2010-11-30 05:09


CAMBRIDGE, Mass. (November 29, 2010) – Whitehead Institute researchers have shown in mouse models that overexpression of the microRNA 125b (miR-125b) can independently cause leukemiaterm and accelerate the disease's progression. Their results are published in this week's online edition of the Proceedings of the National Academy of Sciences (PNAS).

read more | 2400 reads

X-rays linked to increased childhood leukemia risk
By Dross at 2010-10-04 21:00

Berkeley – Diagnostic X-rays may increase the risk of developing childhood leukemiaterm, according to a new study by researchers at the University of California, Berkeley's School of Public Health.

read more | 1 comment | 2690 reads

Researcher at Childrens Hospital LA discovers way to overcome radiation resistance in leukemia
By Dross at 2010-10-01 22:19

LOS ANGELES (September 29, 2010) – A team of researchers lead by Fatih M. Uckun, MD, PhD, of The Saban Research Institute of Childrens Hospital Los Angeles has determined that radiation resistance in leukemiaterm can be overcome by selectively attacking a molecular target known as SYK tyrosine kinase.

B-lineage acute lymphoblastic leukemia (ALL) is the most common cancer occurring in children and adolescents. Despite having received intensive chemotherapyterm, some patients have recurring disease, known as relapse. For these individuals, the prospect of long-term survival is poor.

read more | 1 comment | 2474 reads

Drug in new class of targeted therapies shows early promise against blood-related cancers
By Dross at 2010-05-20 22:10

HACKENSACK, N.J. (May 19, 2010) — A Phase I clinical trial of SNS-032, one of the first in a new class of drugs that inhibit cyclin-dependent kinases, demonstrated the drug's safety and potential clinical action against advanced chronic lymphocytic leukemiaterm (CLL). Cyclin-dependent kinases are enzymatic proteins that are integrally involved in cellular metabolism, renewal and signaling, and are thought to play key roles in the growth of cancers.

read more | 2303 reads

Yet another cancer gene discovered
By Dross at 2009-10-15 10:42

A new cancer gene has been discovered by a research group at the Sahlgrenska Academy. The gene causes an insidious form of glandular cancer usually in the head and neck and in women also in the breast. The discovery could lead to quicker and better diagnosis and more effective treatment.

The study is published today in the prestigious scientific journal Proceedings of the National Academy of Sciences (PNAS).

read more | 2492 reads

Mutations Predict Quick Recurrence Of Acute Leukemia
By Dross at 2008-08-18 21:28



The presence of mutations in a particular gene may forecast the quick return of acute leukemiaterm in some people with the disease, a new study shows.

            Researchers at The Ohio State University Comprehensive Cancer Center examined the prognostic importance of mutations in a gene called Wilms tumor 1 (WT1). The study involved 196 patients under age 60 with acute myeloid leukemia (AML) whose leukemic cells had normal-looking chromosomes, a characteristic present in nearly half of adult AML cases.

read more | 2867 reads

First step towards switching off breast cancer and leukaemia
By Dross at 2008-08-08 20:32

Australian scientists have identified a way to 'switch off' a molecule, a key player in the molecular processes that trigger breast cancer and certain forms of leukaemiaterm.

The molecule, known as Gab2, operates downstream of a major breast cancer oncogene, HER2, the target of the drug Herceptin.

A research team from the Garvan Institute of Medical Research, led by Professor Roger Daly, has found a novel way of blocking signals to and from Gab2, preventing it from fulfilling its role in cell proliferation. The finding is published online today in the EMBO Journal.

In 2002, Professor Daly identified the important role of Gab2 in breast cancer. His task since then has been to work out exactly how Gab2 functions, and how to stop it.

read more | 2913 reads

Tumor-inhibiting protein could be effective in treating leukemia

Angiocidin, a tumor-inhibiting novel protein discovered by Temple University researchers, may also have a role as a new therapeutic application in treating leukemiaterm, according to a study by the researchers.

The study, "The Novel Angiogenic Inhibitor, Angiocidin, Induces Differentiation of Monocytes to Macropahges," will be published in the July 15 issue of the journal Cancer Research ( The research was done by Temple biology doctoral student Anita Gaurnier-Hausser under the direction of George Tuszynski, a professor of neuroscience in Temple's School of Medicine and a professor of biology in Temple's College of Science and Technology.

read more | 2831 reads

Math could help cure leukemia
By Dross at 2008-06-20 22:57

When kids complain that math homework won't help them in real life, a new answer might be that math could help cure cancer.

In a recent study that combined math and medicine, researchers have shown that patients with chronic myelogenous leukemiaterm (CML) may be cured of the disease with an optimally timed cancer vaccine, where the timing is determined based on their own immune response.

In the June 20 edition of the journal PLoS Computational Biology, University of Maryland associate professor of mathematics Doron Levy, Stanford Medical School physician and associate professor of medicine (hematology) Peter P. Lee, and Dr. Peter S. Kim, École Supérieure d'Électricité (Gif-sur-Yvette, France) describe their success in creating a mathematical model which predicts that anti-leukemia immune response in CML patients using the drug imatinib can be stimulated in a way that might provide a cure for the disease.

read more | 2848 reads

Arsenic-based therapy shown to help eradicate leukemia-initiating cells
By Dross at 2008-05-12 21:45

BOSTON -- In both leukemiaterm and solid tumors, there exists among the multitude of warrior cancer cells a small subgroup that work undercover, patiently lying in wait to launch their attacks. Known as either cancer initiating cells (CICs) or leukemia initiating cells (LICs), these stealth populations are impervious to conventional chemotherapyterm and undaunted by targeted cancer therapies. When a leukemia patient relapses following a period of remission, it is the LICs that bear responsibility for the disease’s reemergence.

The secret to the survival abilities of these cells has been unclear. But in a paradoxical discovery, a research team led by investigators at Beth Israel Deaconess Medical Center (BIDMC) has found that a tumor suppressor protein known as PML appears to be the factor that enables LICs to maintain their quiescence – the inert state that protects them from being destroyed by cancer therapies – and suggests that inhibition of PML is a promising target for new therapeutics.

read more | 3003 reads

Syndicate content

sponsored links



Subscribe to our newsletter to receive info on our site or upcoming clinical trials

Confirm your email address

HTML format

Please select the newsletters you want to sign up to:

  • Cancerfocus
    Receive updates from Cancerfocus.
  • Breast
  • Colon
  • Kidney
  • Leukemia
  • Liver
  • Lung
  • Melanoma
  • Mesothelioma
  • Myeloma
  • Neck
  • Pancreatic
  • Prostate

Syndicate content

All times are GMT -5. The time now is 02:26 PM.